The estimated Net Worth of Klaus Orlinger is at least $35.8 Tysiąc dollars as of 16 January 2020. Klaus Orlinger owns over 8,500 units of Hookipa Pharma Inc stock worth over $35,846 and over the last 6 years he sold HOOK stock worth over $0. In addition, he makes $0 as Executive Vice President - Research at Hookipa Pharma Inc.
Klaus has made over 2 trades of the Hookipa Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 8,500 units of HOOK stock worth $850 on 16 January 2020.
The largest trade he's ever made was exercising 8,500 units of Hookipa Pharma Inc stock on 16 January 2020 worth over $850. On average, Klaus trades about 1,545 units every 0 days since 2019. As of 16 January 2020 he still owns at least 6,789 units of Hookipa Pharma Inc stock.
You can see the complete history of Klaus Orlinger stock trades at the bottom of the page.
Dr. Klaus Orlinger was Senior Vice President - Research of the Company. He began leading our research and preclinical departments in 2017, and previously served as our head of virology from 2012 to 2016. From 2008 to 2012, Dr. Orlinger previously led a research team in the Molecular Vaccines Department of Baxter AG.
Klaus Orlinger is 42, he's been the Executive Vice President - Research of Hookipa Pharma Inc since 2020. There are 17 older and no younger executives at Hookipa Pharma Inc. The oldest executive at Hookipa Pharma Inc is Prof. Rolf M. Zinkernagel M.D., Ph.D., 77, who is the Co-Founder.
Klaus's mailing address filed with the SEC is C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY, 10118.
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... oraz Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Hookipa Pharma Inc executives and other stock owners filed with the SEC include: